Philadelphia-area life sciences companies with the largest stock, market cap declines in first half of 2022

Midsize and startup drug developers in the Philadelphia region saw their market capitalization drop by nearly $3.7 billion during the first half of 2022.

Previous Ixonia, Novus add direct mortgage division; lease more office space in Waukesha
Next Syneos Health slashes revenue target amid biotech struggles; stock slides

No Comment

Leave a reply

Your email address will not be published.